Skip to main content

Table 2 Frequency and severity of diary-based symptoms in study participants with upper respiratory infections

From: Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections

Symptom

Frequency (%)*

Severity (mean ± SD)

Placebo

Active

P-value

Placebo

Active

P-value

Cough

29 (78.4%)

7 (25.9%)

< .001

1.73 ± 1.36

0.56 ± 1.01

< .001

Sore throat

30 (81.1%)

13 (48.1%)

008

1.73 ± 1.19

0.74 ± 0.85

.001

Runny nose

25 (67.6%)

18 (66.7%)

1

0.95 ± 0.88

1.56 ± 1.28

.027

Stuffy nose

19 (51.4%)

26 (96.3%)

<.001

0.89 ± 1.05

2.07 ± 0.87

<.001

Malaise

22 (59.5%)

21 (77.8%)

.179

1.49 ± 1.38

1.67 ± 1.03

.572

Fever

4 (10.8%)

0

-

100 – 103 °F

-

 
  1. *Percentage values are compared to the total number of events